Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource, 1 online resource.
Language
Englisch

Bibliographic citation
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma ; volume:92 ; number:1 ; day:23 ; month:5 ; year:2023 ; pages:15-28 ; date:7.2023
Cancer chemotherapy and pharmacology ; 92, Heft 1 (23.5.2023), 15-28, 7.2023

Creator
Rasco, Drew W.
Medina, Theresa
Corrie, Pippa
Pavlick, Anna C.
Middleton, Mark R.
Lorigan, Paul
Hebert, Chris
Plummer, Ruth
Larkin, James
Agarwala, Sanjiv S.
Daud, Adil I.
Qiu, Jiaheng
Bozon, Viviana
Kneissl, Michelle
Barry, Elly
Olszanski, Anthony J.
Contributor
SpringerLink (Online service)

DOI
10.1007/s00280-023-04544-5
URN
urn:nbn:de:101:1-2023091913594856479214
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 8:56 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Rasco, Drew W.
  • Medina, Theresa
  • Corrie, Pippa
  • Pavlick, Anna C.
  • Middleton, Mark R.
  • Lorigan, Paul
  • Hebert, Chris
  • Plummer, Ruth
  • Larkin, James
  • Agarwala, Sanjiv S.
  • Daud, Adil I.
  • Qiu, Jiaheng
  • Bozon, Viviana
  • Kneissl, Michelle
  • Barry, Elly
  • Olszanski, Anthony J.
  • SpringerLink (Online service)

Other Objects (12)

B-Raf specific antibody responses in melanoma patients

B-Raf specific antibody responses in melanoma patients

Neopterin in Patients with Choroidal Melanoma

Neopterin in Patients with Choroidal Melanoma

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

Ipilimumab in patients with melanoma and autoimmune disease

Ipilimumab in patients with melanoma and autoimmune disease

Prognostic factors and medical treatments of patients with melanoma

Hochschulschrift

Prognostic factors and medical treatments of patients with melanoma

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma

Inflammatory landscape in Xeroderma pigmentosum patients with cutaneous melanoma

Inflammatory landscape in Xeroderma pigmentosum patients with cutaneous melanoma

Genetic alteration of Chinese patients with rectal mucosal melanoma

Genetic alteration of Chinese patients with rectal mucosal melanoma

Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf

Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf

Immunological response among patients with undetectable viral load followed for 5 years

Immunological response among patients with undetectable viral load followed for 5 years

Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma

Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma

Related objects